Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreObinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Type de publicationJournal Article
Year of Publication2021
AuteursMorschhauser F, Ghosh N, Lossos IS, M. Palomba L, Mehta A, Casasnovas O, Stevens D, Katakam S, Knapp A, Nielsen T, McCord R, Salles G
JournalBLOOD CANCER JOURNAL
Volume11
Pagination147
Date PublishedAUG 20
Type of ArticleArticle
ISSN2044-5385
Résumé

{We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib/II study (BO29562; NCT02631577). An initial 3 + 3 dose-escalation phase to define the recommended phase II dose of lenalidomide was followed by an expansion phase with G-atezo-len induction and maintenance. At final analysis, 38 patients (lenalidomide 15 mg
DOI10.1038/s41408-021-00539-8